Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT)

Historical Holders from Q4 2019 to Q3 2025

Symbol
IMVT on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
203M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
95.1M
Holdings value
$1.53B
% of all portfolios
0.006%
Grand Portfolio weight change
0%
Number of holders
181
Number of buys
95
Number of sells
-66
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Roivant Sciences Ltd. 55.9% -1.75% $2.81B $414M 113M +17.2% Roivant Sciences Ltd. 12 Dec 2025
FMR LLC 8.4% -17% $237M -$37.9M 14.7M -13.8% FMR LLC 30 Sep 2025
Deep Track Capital, LP 5.59% $145M 9.5M Deep Track Capital, LP 19 Mar 2025

Institutional Holders of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 95.1M $1.53B -$22.9M $16.12 181
2025 Q2 96.2M $1.54B +$26M $16.00 167
2025 Q1 94.1M $1.61B +$222M $17.09 191
2024 Q4 80.1M $1.98B -$11M $24.77 186
2024 Q3 79.2M $2.26B +$130M $28.51 182
2024 Q2 74.7M $1.97B +$94.3M $26.40 195
2024 Q1 70.3M $2.27B +$28.2M $32.31 208
2023 Q4 68.4M $2.88B +$25.9M $42.13 227
2023 Q3 68.1M $2.62B +$462M $38.39 179
2023 Q2 55.5M $1.05B -$33.1M $18.97 145
2023 Q1 58.3M $904M +$20.9M $15.51 140
2022 Q4 56.5M $1B +$261M $17.75 132
2022 Q3 42.7M $238M +$13.9M $5.58 107
2022 Q2 40.1M $156M +$2.27M $3.90 87
2022 Q1 39.5M $218M -$1.33M $5.51 108
2021 Q4 37.8M $322M -$6.09M $8.52 118
2021 Q3 33.8M $293M -$50M $8.69 115
2021 Q2 38.6M $408M -$67.7M $10.57 110
2021 Q1 40.3M $646M -$273M $16.04 118
2020 Q4 40.3M $1.86B +$41.3M $46.19 146
2020 Q3 39.8M $1.4B +$384M $35.19 116
2020 Q2 28.6M $696M +$388M $24.35 87
2020 Q1 12.6M $194M +$20M $15.56 40
2019 Q4 11.3M $176M +$163M $15.87 24